
price close busi august
biomed devic servic
typezero hint broader ambit
bottom line reiter buy rate follow announc
acquir privat diabet softwar compani
lead player develop artifici pancrea diabet decis support
algorithm term deal disclos howev convers
manag suggest acquisit minim impact near-term
result said believ acquisit offer long-term view
icgm design influenc abil interest becom broader
player diabet ecosystem specif previous outlin link
icgm design accompani approv chang paradigm
new product approv partnership open pathway
immedi impact asid approv come form
typezero acquisit bring one degre closer autom
insulin deliveri aid system bring typezero incontrol ap algorithm in-hous
provid abil provid current/futur partner cgm
ap algorithm importantli manag note agreement impact
exist partnership either typezero rather provid
option provid current futur partner net net acquisit unlik
near-term impact view addit typezero posit bring
strateg asset in-hous well strengthen develop abil
addit respect team
import point consid takeaway convers manag
affect typezero partner impact exist
relationship either player note intent compet directli
pump partner beta bionic develop
separ ap algorithm cgm partner tandem slim
control iq slate launch expect first aid product
us incontrol technolog
chang near-term guidanc chang
estim point make futur chang learn
commerci plan tangenti busi model like tier partnership
cgm cgm incontrol stand-alon new product like decis support app
typezero acquisit bring signific horsepow typezero
one lead develop research group within diabet technolog
commun view significantli strengthen group addit
typezero also activ partnership univers virginia
agreement presum strengthen relationship one preemin
academ research group diabet
updat thought stock stock clearli re-rat post robust
continu view posit given underli fundament
global cgm industri broadli also specif launch
still earli inning stick buy take target
updat group multipl
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price august
biomed devic servic
canaccord genuiti estim compani report compani report
buy unchang target price august
biomed devic servic
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin august et
date time product august et
base ev/sal multipl premium high-growth peer group appli revenu estim
price target assum cash debt share outstand
risk achiev target price valuat
market opportun could smaller project cgm could remain nich product patient aggress manag
blood glucos level remain case market penetr diabet popul would substanti
given number player well size competitor would limit opportun within market regulatori
delay could impact futur revenu uncertainti regard regulatori requir fda could delay new product may
impact new product commerci
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
buy unchang target price august
biomed devic servic
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
